Henock Saint Jacques, MD
Cardiovascular Disease · New York, NYNPI 1144207275
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,821 of the $119,472 with a category attached, or 67.6%. 45 manufacturers reported payments, led by Merck at 43.3% of the total. Reporting peaked in 2023 at $47,456 and has fallen 61.6% since, to $18,215 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 767 payments — averaging $155.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$52K
- Scpharmaceuticals Inc.$24K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$12K
- Novartis$10K
- Agepha Pharma FZ LLC$5K
- Amgen$2K
- plus $15K from 39 others
Across 232 payments — averaging $2142.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$297K
- Boehringer Ingelheim International GmbH$101K
- Boehringer Ingelheim Pharma GmbH & Co.kg$99K
- Medtronic$300
What the payments were for
- Consulting fees$4,5004%
- Speaking & faculty fees$80,82168%
- Travel & lodging$10,7039%
- Food & beverage$22,62919%
- Education$540%
- Other$7661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$119,472 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 19 | $382,107 |
| EntrestoSacubitril/Valsartan | 127 | $180,436 |
| VerquvoVericiguat | 85 | $124,499 |
| JardianceEmpagliflozin | 109 | $112,185 |
| FuroscixFurosemide | 14 | $110,755 |
| OzempicSemaglutide | 71 | $103,271 |
| EliquisApixaban | 62 | $69,842 |
| KerendiaFinerenone | 51 | $57,193 |
| Repatha SureclickEvolocumab | 30 | $40,106 |
| Diclofenac Sodium | 71 | $36,171 |
| FarxigaDapagliflozin Propanediol | 29 | $31,130 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $24,907 |
| JanuviaSitagliptin Phosphate | 31 | $24,267 |
| Repatha PushtronexEvolocumab | 13 | $15,850 |
| XareltoRivaroxaban | 18 | $15,765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $1,792 | $382,10719 claims |
| NovartisEntresto | $9,984 | $180,436127 claims |
| MerckVerquvo, Janumet, Januvia | $51,759 | $173,674142 claims |
| Boehringer IngelheimJardiance | $558 | $112,185109 claims |
| Scpharmaceuticals Inc.Furoscix | $23,762 | $110,75514 claims |
| Novo NordiskOzempic | $267 | $103,27171 claims |
| PfizerEliquis | $975 | $69,84262 claims |
| BayerKerendia | $757 | $57,19351 claims |
| AstraZenecaFarxiga | $1,121 | $31,13029 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $63 | $21,14035 claims |
| Johnson & JohnsonXarelto | $236 | $15,76518 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $17 | $12,77917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.